FINWIRES · TerminalLIVE
FINWIRES

Metis TechBio Seeks About HK$2.1 Billion in Hong Kong IPO

By

-- Metis TechBio (HKG:7666) launched its Hong Kong initial public offering on Tuesday, seeking to raise about HK$2.11 billion from the deal.

The China-based AI-driven nanotechnology company is offering 201.2 million shares at HK$10.50 per share, according to a Hong Kong bourse filing.

The offering comprises 10.1 million shares for Hong Kong investors and 191.2 million shares for international investors, subject to reallocation and the overallotment option.

Allocation results are due by May 12, ahead of the company's planned trading debut on May 13.

Net proceeds will be used mainly to fund research and development of AI infrastructure and nanomaterial platforms, as well as support clinical trials of pipeline products.

The funds will also be used to expand into animal health and longevity solutions, build global operations, and for working capital and general corporate purposes.

Jefferies Hong Kong, Deutsche Securities Asia, and CITIC Securities (Hong Kong) are acting as joint sponsors.

Jefferies Hong Kong, Deutsche Bank AG (Hong Kong Branch), and CLSA are serving as overall coordinators and are also acting as joint bookrunners and joint lead managers, alongside CMB International Capital.

Futu Securities International (Hong Kong) is acting as a joint bookrunner and joint lead manager.

Related Articles

Asia

Telix Pharmaceuticals' Investigational Imaging Agent May Potentially Diagnose a Range of Kidney Cancers

Telix Pharmaceuticals' (ASX:TLX) investigational imaging agent TLX250-Px has the potential to help diagnose kidney cancers beyond just clear cell renal cell carcinoma, or ccRCC, the company said Tuesday, citing an independent analysis published in the European Urology scientific journal.The analysis of phase three trial data showed that positive PET scan findings were "highly predictive" of malignancy overall, including in non-clear cell renal cell carcinoma, with a reported positive predictive value of 98%, the company said."Essentially all false-positives for ccRCC in the ZIRCON study have now been shown to be other malignant kidney cancer subtypes, reducing the risk of overtreatment and further supporting clinical adoption," said Telix Group Chief Medical Officer David Cade.

$ASX:TLX
Asia

Huajin International Chairman, CEO Face Consumption Restriction Order

Huajin International (HKG:2738) said its chairman and chief executive were subject to a consumption restriction order due to the alleged nonpayment of amounts owed, according to a Hong Kong bourse filing Tuesday.The company's chairman Xu Songqing and chief executive Chen Chunniu have been subject to the consumption restriction order, effective Nov. 25.The case stems from the alleged non-payment of 130 million yuan by two of the company's units Jiangmen Huamu Metals and Jiangmen Huajin Metal Product, under a finance lease arrangement. As of April 30, 16.4 million yuan was still owed to the creditors.Both Xu and Chen have been negotiating with creditors to resolve the matter and the company expects to reach a settlement by the end of August.

$HKG:2738
Asia

Tata Chemicals' Consolidated Loss Widens in Fiscal Q4

Tata Chemicals' (NSE:TATACHEM, BOM:500770) consolidated attributable loss widened to 21.3 billion Indian rupees in the fiscal fourth quarter ended March 31, from a loss of 1.56 billion rupees a year ago.Loss per share grew to 83.68 rupees compared with a loss per share of 2.19 rupees a year earlier, the chemicals manufacturer said in a filing to the Indian bourses on Monday.Revenue from operations in fiscal Q4 declined to 34.4 billion rupees from 35.1 billion rupees a year ago. This was lower than the 34.8 billion rupees estimated by analysts polled by Visible Alpha.The company's board recommended a dividend of 11 rupees per share for the financial year ended March 31.

$BOM:500770$NSE:TATACHEM